MoAb firm Cytogen to acquire Cellcor
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells to treat cancerand infectious diseases. Cellcor's first product, for treatingrenal cell carcinoma, is in phase III clinical studies.
The transaction will be handled through a stock swap, withCellcor shareholders receiving 0.6 shares of Cytogen stock foreach of the 5.5 million shares of Cellcor common stock. The dealwas valued at $19.5 million by analysts, who said Cellcor wasdown to its last month of cash.
In other Cytogen news, the company filed a new drug application(NDA) with the Food and Drug Administration for Quadramet, a samarium-153-basedagent for the treatment of pain due to cancer that has spreadto the bone. Cytogen has licensed U.S. marketing and manufacturingrights for Quadramet to Du Pont Merck.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
